Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic fatty liver disease (NAFLD)

Abstract

The proportion of hepatocellular carcinoma (HCC) cases due to NAFLD is expected to increase, paralleling the rise in NAFLD due to the obesity epidemic. Early detection is critical, as it potentially enables curative treatment. Current guidelines recommend ultrasound imaging with or without serum AFP measurement in patients with cirrhosis. Unfortunately, several challenges and barriers impede the effective surveillance of HCC in patients with NAFLD. In this review, we focus on four main challenges and barriers: the scale of the NAFLD epidemic, the lack of accurate risk stratification tools, the limitations of available surveillance tools themselves, and the existing disparities in access to care for chronic liver disease. We describe potential solutions, including public health approaches to obesity, improving clinical risk scores using genomic and metabolomic data, improved imaging techniques and blood-based biomarkers, and focusing on underserved groups with liver disease.

Keywords

NAFLD / HCC / non-invasive biomarker / radiomics

References

[1] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018;15:11-20

[2] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[3] Hagström H,Hultcrantz R,Andreasson A.Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study.J Hepatol2016;65:363-8

[4] Zimmermann E,Holst C,Sørensen TI.Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the copenhagen school health records register.BMJ Open2015;5:e006998 PMCID:PMC4420949

[5] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[6] Ioannou GN.Epidemiology and risk-stratification of NAFLD-associated HCC.J Hepatol2021;75:1476-84

[7] Huang DQ,Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2021;18:223-38 PMCID:PMC8016738

[8] Stine JG,Zimmet A.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[9] Singal AG,Narasimman M.HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis.J Hepatol2022;77:128-39 PMCID:PMC9232881

[10] Lin OS,Sanders GD.Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.Aliment Pharmacol Ther2004;19:1159-72

[11] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases.Hepatology2018;67:328-57

[12] Orci LA,Caballol B.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Clin Gastroenterol Hepatol2022;20:283-292.e10

[13] Loomba R,Patton H.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.Gastroenterology2020;158:1822-30 PMCID:PMC8012107

[14] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[15] Younes R,Govaere O.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.J Hepatol2021;75:786-94

[16] Loosen SH,Keitel V,Roderburg C.An elevated FIB-4 score predicts liver cancer development: a longitudinal analysis from 29,999 patients with NAFLD.J Hepatol2022;76:247-8

[17] Vieira Barbosa J,Frick A.Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD.Hepatol Commun2022;6:765-79 PMCID:PMC8948572

[18] Rinella ME,Siddiqui MS.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;

[19] Alexander M,van der Lei J.Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.BMC Med2019;17:95 PMCID:PMC6526616

[20] Jarvis H,Barker R.Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies.PLoS Med2020;17:e1003100 PMCID:PMC7192386

[21] Kimura T,Fujimori N.Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.World J Gastroenterol2018;24:1440-50 PMCID:PMC5889824

[22] Fleischman MW,Zeb I,Foster T.NAFLD prevalence differs among hispanic subgroups: the multi-ethnic study of atherosclerosis.World J Gastroenterol2014;20:4987-93 PMCID:PMC4009531

[23] Gellert-Kristensen H,Davey Smith G,Tybjaerg-Hansen A.Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population.Hepatology2020;72:845-56

[24] Donati B,Romeo S.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Sci Rep2017;7:4492 PMCID:PMC5495751

[25] Nakagawa S,Song WM.Precision liver cancer prevention consortiummolecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition.Cancer Cell2016;30:879-90 PMCID:PMC5161110

[26] Fujiwara N,Crouchet E.Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.Sci Transl Med2022;14:eabo4474 PMCID:PMC9236162

[27] Khan IM,Jiao J.A novel biomarker panel for the early detection and risk assessment of hepatocellular carcinoma in patients with cirrhosis.Cancer Prev Res2021;14:667-74 PMCID:PMC8225562

[28] Duarte-Salles T,Stepien M.Circulating osteopontin and prediction of hepatocellular carcinoma development in a large european population.Cancer Prev Res2016;9:758-65 PMCID:PMC5010922

[29] Mazziotti G,Morisco F.Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.Cancer2002;95:2539-45

[30] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-1718.e1 PMCID:PMC5927818

[31] Colli A,Miletic D.Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.Cochrane Database Syst Rev2021;4:CD013346 PMCID:PMC8078581

[32] Uppot RN.Technical challenges of imaging & image-guided interventions in obese patients.Br J Radiol2018;91:20170931 PMCID:PMC6223172

[33] Marks RM,Heba ER.Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.AJR Am J Roentgenol2015;204:527-35

[34] Vietti Violi N,Hectors S.Radiological diagnosis and characterization of HCC. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 71-92.

[35] Zhou W,Wang K.Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images.J Magn Reson Imaging2017;45:1476-84

[36] Peng J,Zhang Q,Zhou J.A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma.Diagn Interv Radiol2018;24:121-7 PMCID:PMC5951199

[37] Segal E,Ooi C.Decoding global gene expression programs in liver cancer by noninvasive imaging.Nat Biotechnol2007;25:675-80

[38] Johnson PJ,Cox TF.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.Cancer Epidemiol Biomarkers Prev2014;23:144-53

[39] Shen J,Zhang YJ.Genome-wide DNA methylation profiles in hepatocellular carcinoma.Hepatology2012;55:1799-808

[40] Chalasani NP,Bhattacharya A.A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma.Clin Gastroenterol Hepatol2021;19:2597-2605.e4

[41] Chalasani NP,Bhattacharya A.Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma.Clin Gastroenterol Hepatol2022;20:173-182.e7

[42] Lee YT,Wang JJ.The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma.Cancers2021;13:3076 PMCID:PMC8233859

[43] Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[44] von Felden J,Dogra N.Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer.Gut2021:2069-80 PMCID:PMC8795201

[45] Sun N,Zhang RY.Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.Nat Commun2020;11:4489 PMCID:PMC7477161

[46] Sun N,Lee YT.HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.Hepatology2023;77:774-88 PMCID:PMC9887095

[47] Yeo YH,Jeong D.Surveillance of patients with cirrhosis remains suboptimal in the United States.J Hepatol2021;75:856-64

[48] Tavakoli H,Liu B.Cirrhosis patients with nonalcoholic steatohepatitis are significantly less likely to receive surveillance for hepatocellular carcinoma.Dig Dis Sci2017;62:2174-81

[49] Mittal S,El-Serag HB.Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.Clin Gastroenterol Hepatol2015;13:594-601.e1 PMCID:PMC4333060

[50] Farvardin S,Khambaty M.Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.Hepatology2017;65:875-84 PMCID:PMC5568252

[51] Singal AG,Tiro J.Racial, social, and clinical determinants of hepatocellular carcinoma surveillance.Am J Med2015;128:90.e1-7 PMCID:PMC4282818

[52] Davila JA,Richardson PA,McGlynn KA.Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.Hepatology2010;52:132-41 PMCID:PMC3835698

[53] Davila JA,Kramer JR.Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.Ann Intern Med2011;154:85-93

[54] Li DJ,Vachharajani N,Garonzik-Wang J.Physician-patient communication is associated with hepatocellular carcinoma screening in chronic liver disease patients.J Clin Gastroenterol2017;51:454-60

[55] Henson JB,Patel YA,Muir AJ.Access to technology to support telehealth in areas without specialty care for liver disease.Hepatology2023;77:176-85